Oragenics Inc. Watch

from 8-K 31 pages Oragenics, Inc. Common Stock Atm Sales Agreement

from SC 13G 1 page Joint Filing Agreement Pursuant to Rule 13d-1

from 8-K 24 pages Placement Agency Agreement

from 8-K 23 pages Placement Agency Agreement

from 8-K 68 pages Underwriting Agreement Between Oragenics, Inc. and Thinkequity LLC as Representative of the Several Underwriters Oragenics, Inc. Underwriting Agreement

from 8-K 42 pages At the Market Offering Agreement

from 8-K 40 pages Oragenics, Inc. Common Stock Sales Agreement

from 8-K 8 pages This Letter (The “Agreement”) Constitutes the Agreement Between A.G.P./ALLIANCE Global Partners, as the Sole Placement Agent (“A.G.P.”) (A.G.P. Is Also Referred to Herein as the “Placement Agent” or the “Placement Agents”), and Oragenics, Inc., a Company Incorporated Under the Laws of Florida (The “Company”), That the Placement Agents Shall Serve as the Placement Agents for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of Shares of Common Stock, Par Value, $0.001 Per Share (The “Shares”). the Shares Actually Placed by the Placement Agents Are Referred to Herein as the “Placement Agent Securities.” the Placement Agent Securities Shall Be Offered and Sold Under the Company’s Registration Statement on Form S-3 (File No. 333-235763) With Respect to the Placement Agent Securities. the Documents Executed and Delivered by the Company and the Purchasers (As Defined Below) in Connection With the Placement, Including, Without Limitation, a Securities Purchase Agreement (The “Purchase Agreement”), Shall Be Collectively Referred to Herein as the “Transaction Documents.” the Purchase Price to the Purchasers for Each Share Is $0.45. the Placement Agents May Retain Other Brokers or Dealers to Act as Sub-Agents or Selected-Dealers on Its Behalf in Connection With the Placement. the Placement Agent Hereby Waives the Limitations Imposed on the Offer, Pledge, Issuance, Sale, and Contract to Sell Shares of Common Stock Contained in Section 5(l) of That Certain Underwriting Agreement Dated November 19, 2020 Between the Placement Agent and the Company

from 8-K 30 pages Oragenics, Inc. Underwriting Agreement 14,189,189 Shares of Common Stock

from 8-K 42 pages 16,666,668 Shares of Common Stock 8,333,334 Series 1 Warrants and 8,333,334 Series 2 Warrants of Oragenics, Inc. Underwriting Agreement

from 8-K 43 pages 2,636,000 Shares of Common Stock 9,364,000 Shares of Series D Convertible Preferred Stock (Convertible Into 9,364,000 Shares of Common Stock) and 12,000,000 Warrants of Oragenics, Inc. Underwriting Agreement

from S-1/A 43 pages Shares of Common Stock Shares of Series a Convertible Preferred Stock (Convertible Into Shares of Common Stock) and Warrants of Oragenics, Inc. Underwriting Agreement

from 8-K 16 pages Placement Agency Agreement April 6, 2018

from SC 13D/A 1 page Joint Filing Agreement

from 8-K 25 pages 4,400,000 Shares Oragenics, Inc. Common Stock Underwriting Agreement

from S-1/A 32 pages Oragenics, Inc. Shares1 Common Stock ($0.001 Par Value) Underwriting Agreement

from 8-K 4 pages Revolving Unsecured Promissory Note

from 8-K 4 pages Unsecured Promissory Note With Conversion Provisions

from SB-2/A ~10 pages Oragenics, Inc. Agency Agreement

from SB-2/A ~5 pages Exhibit 1.1 July 29, 2002